furosemide has been researched along with Left Ventricular Dysfunction in 45 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Elderly patients with heart failure are at risk of postprandial hypotension (PPH), orthostatic hypotension (OH), and concomitant cerebral oxygenation changes because of altered cardiovascular balance and the use of cardiovascular medications, such as furosemide and captopril." | 9.10 | Effects of furosemide versus captopril on postprandial and orthostatic blood pressure and on cerebral oxygenation in patients > or = 70 years of age with heart failure. ( Colier, WN; Hoefnagels, WH; Jansen, RW; Mehagnoul-Schipper, DJ; Verheugt, FW, 2002) |
| "The objective of this study was to determine whether the addition of low-dose (renal-dose) dopamine to furosemide therapy enhances natriuresis in patients with compensated congestive heart failure, New York Heart Association Class II or III." | 9.08 | Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. ( Brater, DC; Rudy, DW; Swan, SK; Vargo, DL, 1996) |
| "Clinical data are scarce for furosemide administered as a low-dose (<160 mg/24 hours) continuous intravenous infusion in acute heart failure (HF)." | 7.78 | Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety. ( Chan, CY; Elkayam, U; Hshieh, S; Ng, TM, 2012) |
| " Here, we compared the effects of tolvaptan, a newly developed nonpeptide V(2) receptor antagonist, with those of furosemide, a loop diuretic, and a combination of these 2 agents in rats with left ventricular dysfunction after myocardial infarction (MI)." | 7.78 | Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. ( Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M, 2012) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 7.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "In patients with decompensated chronic congestive heart failure (CHF), intensive unloading therapy allows an acute decrease in ventricular filling pressures and improves long-term prognosis." | 6.71 | Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. ( Cioffi, G; Opasich, C; Stefenelli, C; Tarantini, L, 2003) |
| " All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12." | 6.68 | The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995) |
| " We analyzed the degree of cross-linking and the expression of the enzyme lysyl oxidase, which regulates cross-linking, in the myocardium of patients with chronic heart failure at baseline and after 8 months of treatment with either torasemide or furosemide in addition to their standard heart failure therapy." | 5.14 | Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. ( Beaumont, J; Díez, J; González, A; Larman, M; López, B; Querejeta, R, 2009) |
| "Elderly patients with heart failure are at risk of postprandial hypotension (PPH), orthostatic hypotension (OH), and concomitant cerebral oxygenation changes because of altered cardiovascular balance and the use of cardiovascular medications, such as furosemide and captopril." | 5.10 | Effects of furosemide versus captopril on postprandial and orthostatic blood pressure and on cerebral oxygenation in patients > or = 70 years of age with heart failure. ( Colier, WN; Hoefnagels, WH; Jansen, RW; Mehagnoul-Schipper, DJ; Verheugt, FW, 2002) |
| "The effect of torasemide and furosemide therapy was compared in 50 patients who had chronic heart failure and symptoms [NYHA class II-III] despite long-term therapy with both low-dose furosemide and angiotensin-converting enzyme inhibitors." | 5.10 | Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. ( Akutagawa, O; Fukuda, M; Hayashi, T; Honda, K; Okamoto, M; Sasaki, T; Yamato, M, 2003) |
| "The objective of this study was to determine whether the addition of low-dose (renal-dose) dopamine to furosemide therapy enhances natriuresis in patients with compensated congestive heart failure, New York Heart Association Class II or III." | 5.08 | Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. ( Brater, DC; Rudy, DW; Swan, SK; Vargo, DL, 1996) |
| "Previous literature has suggested a potential diuretic sparing effect as early as 6 months following sacubitril-valsartan initiation in patients with heart failure with reduced ejection fraction (HFrEF); however, whether this effect manifests earlier after initiation is unclear." | 4.12 | Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. ( Beavers, JC; Orvin, NJ; Russell, SD, 2022) |
| "The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical, laboratory and echocardiographic parameters and outcomes in a real-world population with heart failure with reduced ejection fraction (HFrEF)." | 3.96 | Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction. ( Auria, F; Bonadies, D; Carrizzo, A; Ciccarelli, M; Citro, R; De Angelis, E; Galasso, G; Gigantino, A; Iaccarino, G; Loria, F; Polito, MV; Rispoli, A; Silverio, A; Vecchione, C; Vitulano, G, 2020) |
| " The goal of this study is to investigate the relationship between daily doses of furosemide and the outcomes of patients with left ventricular dysfunction (LVD) from the viewpoint of cardiac SNS abnormalities using iodine-123-labeled metaiodobenzylguanidine (l-MIBG) myocardial scintigraphy." | 3.91 | Impact of short-acting loop diuretic doses and cardiac sympathetic nerve abnormalities on outcomes of patients with reduced left ventricular function. ( Ideguchi, T; Ishikawa, T; Kitamura, K; Koyama, S; Nagamachi, S; Onitsuka, H, 2019) |
| "To ascertain whether increasing doses of orally administered furosemide are associated with impaired survival in outpatients with chronic heart failure (CHF) and left ventricular (LV) systolic dysfunction." | 3.79 | Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. ( Cicoira, M; Dini, FL; Genta, FT; Ghio, S; Klersy, C; Rossi, A; Scelsi, L; Simioniuc, A; Tavazzi, L; Temporelli, PL, 2013) |
| "Clinical data are scarce for furosemide administered as a low-dose (<160 mg/24 hours) continuous intravenous infusion in acute heart failure (HF)." | 3.78 | Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety. ( Chan, CY; Elkayam, U; Hshieh, S; Ng, TM, 2012) |
| " Here, we compared the effects of tolvaptan, a newly developed nonpeptide V(2) receptor antagonist, with those of furosemide, a loop diuretic, and a combination of these 2 agents in rats with left ventricular dysfunction after myocardial infarction (MI)." | 3.78 | Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. ( Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M, 2012) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 3.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "MDC of HF remains cost-beneficial when combined with optimal, medical care." | 2.71 | Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? ( Barry, M; Cahill, J; Ledwidge, M; Maurer, B; McDonald, K; Ryan, E; Ryder, M; Timmons, L; Travers, B, 2003) |
| "In patients with decompensated chronic congestive heart failure (CHF), intensive unloading therapy allows an acute decrease in ventricular filling pressures and improves long-term prognosis." | 2.71 | Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. ( Cioffi, G; Opasich, C; Stefenelli, C; Tarantini, L, 2003) |
| "N-BNP-guided treatment of heart failure reduced total cardiovascular events, and delayed time to first event compared with intensive clinically guided treatment." | 2.69 | Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. ( Espiner, EA; Frampton, CM; Nicholls, MG; Richards, AM; Troughton, RW; Yandle, TG, 2000) |
| " All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12." | 2.68 | The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995) |
| "A diagnosis of dilated cardiomyopathy with cardiorenal syndrome was made, most likely secondary to viral myocarditis in view of his initial presentation." | 1.42 | The failing heart: a bad case of the 'flu'. ( Akhtar, MM; Emmanuel, J; Modi, B; Wilson, J, 2015) |
| "Echocardiography detected left ventricular hypertrophy and diastolic dysfunction." | 1.39 | Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. ( Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A, 2013) |
| " Actually, a significant association with ARD was not present in any CHF patient with dilated left ventricle treated with high dosage of iv FUR, whereas a highly significant association with ARD was observed in HFNEF patients (OR: 72 95% CI: 6." | 1.37 | In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function. ( Ariano, C; Cantatrione, S; Ciccarelli, A; Cioppa, C; De Vecchis, R; Giasi, A; Pucciarelli, A, 2011) |
| "Transcatheter closure of atrial septal defects (ASDs) is a safe and effective treatment." | 1.33 | Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of atrial septal defect. ( Abdul-Khaliq, H; Ewert, P; Lange, PE; Nagdyman, N; Peters, B; Schubert, S, 2005) |
| "This report describes a patient with the pulmonary edema after cardioversion for paroxysmal atrial flutter without organic heart disease." | 1.31 | Pulmonary edema after cardioversion for paroxysmal atrial flutter: left ventricular diastolic dysfunction induced by direct current shock. ( Kobayashi, N; Ochi, T; Saito, M; Takayama, M; Ushimaru, H; Yamaura, S, 2000) |
| "Patients with left ventricular dysfunction have a disturbance of the normal reciprocal relationship between PARC and ANP which antedates diuretic treatment." | 1.30 | Disruption of the relationship between renin and atrial natriuretic peptide early in the course of ventricular dysfunction. ( Cleland, JG; Dutka, DP; Puri, S; Strong, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (11.11) | 18.2507 |
| 2000's | 23 (51.11) | 29.6817 |
| 2010's | 14 (31.11) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Polito, MV | 1 |
| Silverio, A | 1 |
| Rispoli, A | 1 |
| Vitulano, G | 1 |
| Auria, F | 1 |
| De Angelis, E | 1 |
| Loria, F | 1 |
| Gigantino, A | 1 |
| Bonadies, D | 1 |
| Citro, R | 1 |
| Carrizzo, A | 1 |
| Galasso, G | 1 |
| Iaccarino, G | 1 |
| Vecchione, C | 1 |
| Ciccarelli, M | 1 |
| Orvin, NJ | 1 |
| Beavers, JC | 1 |
| Russell, SD | 1 |
| Ekici, B | 1 |
| Yaman, M | 1 |
| Küçük, M | 1 |
| Dereli, S | 1 |
| Yenerçağ, M | 1 |
| Yiğit, Z | 1 |
| Baş, MM | 1 |
| Karavelioğlu, Y | 1 |
| Çakmak, HA | 1 |
| Kıvrak, T | 1 |
| Özkan, H | 1 |
| Altın, C | 1 |
| Şabanoğlu, C | 1 |
| Demirkan, B | 1 |
| Ataş, AE | 1 |
| Kılıçaslan, F | 1 |
| Altay, H | 1 |
| Tengiz, İ | 1 |
| Fahri Erkan, A | 1 |
| Kılıçaslan, B | 1 |
| Olgun, FE | 1 |
| Durakoğlugil, ME | 1 |
| Alhan, A | 1 |
| Zoghi, M | 1 |
| Onitsuka, H | 1 |
| Koyama, S | 1 |
| Ideguchi, T | 1 |
| Ishikawa, T | 2 |
| Kitamura, K | 1 |
| Nagamachi, S | 1 |
| Yokokawa, T | 1 |
| Nakazato, K | 1 |
| Kanno, Y | 1 |
| Mizukami, H | 1 |
| Kobayashi, A | 1 |
| Yoshihisa, A | 1 |
| Takahashi, H | 1 |
| Shichishima-Nakamura, A | 1 |
| Ohkawara, H | 1 |
| Noji, H | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Ogawa, K | 1 |
| Hisa, S | 1 |
| Takeishi, Y | 1 |
| Dini, FL | 1 |
| Ghio, S | 1 |
| Klersy, C | 1 |
| Rossi, A | 1 |
| Simioniuc, A | 1 |
| Scelsi, L | 1 |
| Genta, FT | 1 |
| Cicoira, M | 1 |
| Tavazzi, L | 1 |
| Temporelli, PL | 1 |
| Yamazaki, T | 2 |
| Nakamura, Y | 2 |
| Shiota, M | 2 |
| Osada-Oka, M | 2 |
| Fujiki, H | 2 |
| Hanatani, A | 2 |
| Shimada, K | 2 |
| Miura, K | 1 |
| Yoshiyama, M | 2 |
| Iwao, H | 2 |
| Izumi, Y | 2 |
| Wilson, J | 1 |
| Akhtar, MM | 1 |
| Modi, B | 1 |
| Emmanuel, J | 1 |
| Buggey, J | 1 |
| Mentz, RJ | 1 |
| Pitt, B | 1 |
| Eisenstein, EL | 1 |
| Anstrom, KJ | 1 |
| Velazquez, EJ | 1 |
| O'Connor, CM | 1 |
| Shyamali, NL | 1 |
| Ranawaka, H | 1 |
| Cadrin-Tourigny, J | 1 |
| Fournier, A | 1 |
| Andelfinger, G | 1 |
| Khairy, P | 1 |
| López, B | 1 |
| Querejeta, R | 1 |
| González, A | 1 |
| Beaumont, J | 1 |
| Larman, M | 1 |
| Díez, J | 1 |
| Altenberger, H | 1 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 2 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| De Vecchis, R | 1 |
| Ciccarelli, A | 1 |
| Ariano, C | 1 |
| Cioppa, C | 1 |
| Giasi, A | 1 |
| Pucciarelli, A | 1 |
| Cantatrione, S | 1 |
| Kim, DY | 1 |
| Islam, S | 1 |
| Mondal, NT | 1 |
| Mussell, F | 1 |
| Rauchholz, M | 1 |
| Besancon, A | 1 |
| Schmitt, C | 1 |
| Glaizal, M | 1 |
| Tichadou, L | 1 |
| Klouche, K | 1 |
| Hayek-Lanthois, M | 1 |
| de Haro, L | 1 |
| Ng, TM | 1 |
| Hshieh, S | 1 |
| Chan, CY | 1 |
| Elkayam, U | 1 |
| Yamashita, N | 1 |
| Mekontso Dessap, A | 1 |
| Roche-Campo, F | 1 |
| Kouatchet, A | 1 |
| Tomicic, V | 1 |
| Beduneau, G | 1 |
| Sonneville, R | 1 |
| Cabello, B | 1 |
| Jaber, S | 1 |
| Azoulay, E | 1 |
| Castanares-Zapatero, D | 1 |
| Devaquet, J | 1 |
| Lellouche, F | 1 |
| Katsahian, S | 1 |
| Brochard, L | 1 |
| Mehagnoul-Schipper, DJ | 1 |
| Colier, WN | 1 |
| Hoefnagels, WH | 1 |
| Verheugt, FW | 1 |
| Jansen, RW | 1 |
| Yamato, M | 1 |
| Sasaki, T | 1 |
| Honda, K | 1 |
| Fukuda, M | 1 |
| Akutagawa, O | 1 |
| Okamoto, M | 1 |
| Ledwidge, M | 1 |
| Barry, M | 1 |
| Cahill, J | 1 |
| Ryan, E | 1 |
| Maurer, B | 1 |
| Ryder, M | 1 |
| Travers, B | 1 |
| Timmons, L | 1 |
| McDonald, K | 1 |
| Cioffi, G | 1 |
| Stefenelli, C | 1 |
| Tarantini, L | 1 |
| Opasich, C | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Ohnishi, M | 1 |
| Tsutsui, T | 1 |
| Ishii, C | 1 |
| Ohno, K | 1 |
| Fujii, M | 1 |
| Matsumoto, T | 1 |
| Yamamoto, T | 1 |
| Takayama, T | 1 |
| Dohke, T | 1 |
| Horie, M | 1 |
| Kasama, S | 1 |
| Toyama, T | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Ichikawa, S | 1 |
| Suzuki, T | 1 |
| Kurabayashi, M | 1 |
| McCurley, JM | 1 |
| Hanlon, SU | 1 |
| Wei, SK | 1 |
| Wedam, EF | 1 |
| Michalski, M | 1 |
| Haigney, MC | 1 |
| Weber, KT | 1 |
| Schubert, S | 1 |
| Peters, B | 1 |
| Abdul-Khaliq, H | 1 |
| Nagdyman, N | 1 |
| Lange, PE | 1 |
| Ewert, P | 1 |
| Chuen, MJ | 1 |
| MacFadyen, RJ | 1 |
| Lewis, E | 1 |
| Stacey, MR | 1 |
| Ennezat, PV | 1 |
| Gonin, X | 1 |
| Darchis, J | 1 |
| De Groote, P | 1 |
| Lamblin, N | 1 |
| Bauters, C | 1 |
| Lejemtel, T | 1 |
| Asseman, P | 1 |
| Gupta, N | 1 |
| Dalmia, S | 1 |
| Deka, D | 1 |
| Mittal, S | 1 |
| Reed, S | 1 |
| Greene, P | 1 |
| Ryan, T | 1 |
| Cerimele, B | 1 |
| Schwertschlag, U | 1 |
| Weinberger, M | 1 |
| Voelker, J | 1 |
| Vargo, DL | 1 |
| Brater, DC | 1 |
| Rudy, DW | 1 |
| Swan, SK | 1 |
| Koller-Strametz, J | 1 |
| Pacher, R | 1 |
| Frey, B | 1 |
| Kos, T | 1 |
| Woloszczuk, W | 1 |
| Stanek, B | 1 |
| Nakagawa, C | 1 |
| Sakaguchi, Y | 1 |
| Nakajima, T | 1 |
| Kawamoto, A | 1 |
| Uemura, S | 1 |
| Fujimoto, S | 1 |
| Hashimoto, T | 1 |
| Dohi, K | 1 |
| Shirai, T | 1 |
| Kobayashi, N | 1 |
| Takayama, M | 1 |
| Yamaura, S | 1 |
| Ushimaru, H | 1 |
| Ochi, T | 1 |
| Saito, M | 1 |
| Sirivella, S | 1 |
| Gielchinsky, I | 1 |
| Parsonnet, V | 1 |
| Troughton, RW | 1 |
| Frampton, CM | 1 |
| Yandle, TG | 1 |
| Espiner, EA | 1 |
| Nicholls, MG | 1 |
| Richards, AM | 1 |
| Dutka, DP | 1 |
| Puri, S | 1 |
| Strong, R | 1 |
| Cleland, JG | 1 |
| Knowles, JW | 1 |
| Esposito, G | 1 |
| Mao, L | 1 |
| Hagaman, JR | 1 |
| Fox, JE | 1 |
| Smithies, O | 1 |
| Rockman, HA | 1 |
| Maeda, N | 1 |
| Johnson, A | 1 |
| Mackway-Jones, K | 1 |
| Charniot, JC | 1 |
| Alexeeva, A | 1 |
| Laurent, S | 1 |
| Zerhouni, K | 1 |
| Barthélemy, B | 1 |
| Cohen, R | 1 |
| Krivitzky, A | 1 |
| Artigou, JY | 1 |
| Herholz, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Weaning of Mechanical Ventilation Guided by the Natriuretic Peptide of Type B[NCT00473148] | Phase 3 | 265 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| HF Assessment With BNP in the Home: Part II[NCT02351063] | 1 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Sponsor's discretion to terminate study prematurely for further evaluation.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for furosemide and Left Ventricular Dysfunction
| Article | Year |
|---|---|
A reappraisal of loop diuretic choice in heart failure patients.
Topics: Choice Behavior; Fibrosis; Furosemide; Heart; Heart Failure; Humans; Myocardium; Practice Patterns, | 2015 |
11 trials available for furosemide and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure.
Topics: Aged; Collagen; Diuretics; Dose-Response Relationship, Drug; Female; Furosemide; Heart Failure; Hear | 2009 |
Natriuretic peptide-driven fluid management during ventilator weaning: a randomized controlled trial.
Topics: Acetazolamide; Aged; Diuretics; Female; Furosemide; Humans; Male; Middle Aged; Natriuretic Peptide, | 2012 |
Effects of furosemide versus captopril on postprandial and orthostatic blood pressure and on cerebral oxygenation in patients > or = 70 years of age with heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Cerebr | 2002 |
Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Echocardiograp | 2003 |
Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cost-Benefit Analysis; Decision M | 2003 |
Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure.
Topics: Age Factors; Aged; Aged, 80 and over; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Male; | 2003 |
Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Atrial Natriuretic Factor; Cardiotonic Agents; Dopamine; Drug Combinati | 2004 |
The renin angiotensin aldosterone system and frusemide response in congestive heart failure.
Topics: Administration, Oral; Aged; Aldosterone; Captopril; Cross-Over Studies; Drug Therapy, Combination; F | 1995 |
Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure.
Topics: Aged; Diuretics; Dopamine; Drug Interactions; Female; Furosemide; Glomerular Filtration Rate; Heart | 1996 |
Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery.
Topics: Acute Kidney Injury; Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Diuretics; Dopamine; Dru | 2000 |
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Digoxin; Diure | 2000 |
33 other studies available for furosemide and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arterial Pressure; Biphenyl Compounds; Cardi | 2020 |
Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Diuretics; Drug Combinations; Furosemide; Heart Fa | 2022 |
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinat | 2021 |
Impact of short-acting loop diuretic doses and cardiac sympathetic nerve abnormalities on outcomes of patients with reduced left ventricular function.
Topics: 3-Iodobenzylguanidine; Aged; Biological Availability; Dose-Response Relationship, Drug; Female; Furo | 2019 |
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome.
Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertens | 2013 |
Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, D | 2013 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibr | 2013 |
The failing heart: a bad case of the 'flu'.
Topics: Ascites; Cardio-Renal Syndrome; Cardiomyopathy, Dilated; Diagnosis, Differential; Diuretics; Echocar | 2015 |
Takotsubo cardiomyopathy after an emotional outburst.
Topics: Antihypertensive Agents; Aspirin; Carbazoles; Carvedilol; Diuretics; Echocardiography; Family Confli | 2015 |
Severe left ventricular dysfunction in infants with ventricular preexcitation.
Topics: Adrenergic alpha-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilate | 2008 |
Isolated left ventricular hypertrabeculation/noncompaction in a Turner mosaic with male phenotype.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, | 2009 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
Topics: Aged; Aged, 80 and over; Algorithms; Analysis of Variance; Biomarkers; Case-Control Studies; Chronic | 2011 |
Biventricular thrombi associated with peripartum cardiomyopathy.
Topics: Bangladesh; Cardiomyopathies; Drug Combinations; Echocardiography; Enalapril; Female; Furosemide; Hu | 2011 |
[Occurrence of severe cardiac alterations in Amanita proxima poisoning: two original observations].
Topics: Adrenergic beta-Agonists; Adult; Amanita; Diuretics; Dobutamine; Electrocardiography; Female; Furose | 2012 |
Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety.
Topics: Acute Kidney Injury; Adult; Aged; Cohort Studies; Diuretics; Female; Furosemide; Heart Failure; Hear | 2012 |
Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Dose-Respo | 2012 |
Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Case-Control Studies | 2004 |
Furosemide and the progression of left ventricular dysfunction in experimental heart failure.
Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Biomarkers; Disease Models, Animal; Disease Progress | 2004 |
Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain.
Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Diuretics; Electrolytes; Furosemide; Heart Failure; | 2004 |
Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of atrial septal defect.
Topics: Aged; Aged, 80 and over; Cardiac Catheterization; Cardiotonic Agents; Catheterization; Diuretics; Do | 2005 |
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bumetanide; California; Creatinine; Diuretics; Dose-Resp | 2006 |
Cardiorespiratory symptoms in pregnancy: not always pulmonary embolism.
Topics: Cardiomyopathies; Cesarean Section; Chest Pain; Diagnosis, Differential; Diuretics; Dyspnea; Echocar | 2007 |
Delayed recovery of left ventricular systolic dysfunction: ''give time to medical therapy''.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Diuretics; Drug T | 2007 |
Successful maternal and fetal outcome in a pregnancy with type V Takayasu's aortoarteritis.
Topics: Adult; Antihypertensive Agents; Arterial Occlusive Diseases; Calcium Channel Blockers; Diuretics; Fe | 2008 |
Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.
Topics: Adrenergic Agonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiotonic | 1998 |
A case of eosinophilic myocarditis complicated by Kimura's disease (eosinophilic hyperplastic lymphogranuloma) and erythroderma.
Topics: Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; Biopsy; Cardiomegaly; Dermati | 1999 |
Pulmonary edema after cardioversion for paroxysmal atrial flutter: left ventricular diastolic dysfunction induced by direct current shock.
Topics: Aged; Atrial Flutter; Electric Countershock; Electrocardiography; Furosemide; Humans; Male; Nitrogly | 2000 |
Disruption of the relationship between renin and atrial natriuretic peptide early in the course of ventricular dysfunction.
Topics: Atrial Natriuretic Factor; Blood Volume; Diuretics; Female; Furosemide; Humans; Male; Middle Aged; N | 1999 |
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Enalapril; Furosemide; Guanylate Cyc | 2001 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Frusemide or nitrates in acute left ventricular failure.
Topics: Aged; Aged, 80 and over; Evidence-Based Medicine; Furosemide; Heart Failure; Humans; Male; Nitrates; | 2001 |
[Reversible hypokinetic cardiomyopathy revealing severe hypocalcemia].
Topics: Calcifediol; Calcium; Cardiomyopathy, Dilated; Diuretics; Echocardiography; Electrocardiography; Fem | 2001 |
[Emergency care in acute left heart failure. Decreasing preload, oxygen inhalation].
Topics: Administration, Inhalation; Aged; Combined Modality Therapy; Emergency Medical Services; Family Prac | 2001 |